Xponance Inc. Buys 410 Shares of Perrigo Company plc (NYSE:PRGO)

Xponance Inc. increased its stake in shares of Perrigo Company plc (NYSE:PRGO) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,153 shares of the company’s stock after acquiring an additional 410 shares during the quarter. Xponance Inc.’s holdings in Perrigo were worth $649,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC purchased a new position in shares of Perrigo during the third quarter valued at approximately $119,000. UMB Bank n.a. increased its stake in shares of Perrigo by 4.1% during the third quarter. UMB Bank n.a. now owns 33,947 shares of the company’s stock valued at $1,085,000 after buying an additional 1,342 shares during the period. Handelsbanken Fonder AB increased its stake in shares of Perrigo by 14.4% during the third quarter. Handelsbanken Fonder AB now owns 23,000 shares of the company’s stock valued at $735,000 after buying an additional 2,900 shares during the period. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Perrigo by 12.1% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 9,247 shares of the company’s stock valued at $295,000 after buying an additional 1,000 shares during the period. Finally, Linden Thomas Advisory Services LLC purchased a new position in shares of Perrigo during the third quarter valued at approximately $638,000. 95.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PRGO shares. JPMorgan Chase & Co. reduced their target price on Perrigo from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th. Piper Sandler lifted their price target on Perrigo from $35.00 to $39.00 and gave the company an “overweight” rating in a research report on Monday, April 8th. Canaccord Genuity Group restated a “buy” rating and set a $42.00 price target on shares of Perrigo in a research report on Friday, April 12th. Finally, StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd.

Perrigo Trading Up 2.1 %

Perrigo stock opened at $31.94 on Friday. The company has a current ratio of 1.79, a quick ratio of 1.07 and a debt-to-equity ratio of 0.76. The business’s fifty day simple moving average is $30.52 and its two-hundred day simple moving average is $30.80. Perrigo Company plc has a 12 month low of $25.77 and a 12 month high of $40.28. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of -319.40 and a beta of 0.64.

Perrigo (NYSE:PRGO) last released its earnings results on Tuesday, February 27th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, equities analysts predict that Perrigo Company plc will post 2.55 earnings per share for the current fiscal year.

Perrigo Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 26th. Stockholders of record on Friday, March 8th were paid a $0.276 dividend. The ex-dividend date was Thursday, March 7th. This represents a $1.10 annualized dividend and a dividend yield of 3.46%. This is a boost from Perrigo’s previous quarterly dividend of $0.27. Perrigo’s payout ratio is currently -1,100.00%.

Insider Transactions at Perrigo

In other Perrigo news, EVP Alison Ives purchased 2,490 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was purchased at an average price of $27.26 per share, for a total transaction of $67,877.40. Following the completion of the purchase, the executive vice president now directly owns 16,122 shares of the company’s stock, valued at $439,485.72. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Perrigo news, EVP Alison Ives purchased 2,490 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was purchased at an average price of $27.26 per share, for a total transaction of $67,877.40. Following the completion of the purchase, the executive vice president now directly owns 16,122 shares of the company’s stock, valued at $439,485.72. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert Willis acquired 6,000 shares of Perrigo stock in a transaction that occurred on Thursday, February 29th. The shares were purchased at an average price of $25.87 per share, with a total value of $155,220.00. Following the transaction, the executive vice president now owns 25,105 shares of the company’s stock, valued at approximately $649,466.35. The disclosure for this purchase can be found here. Insiders acquired 17,990 shares of company stock worth $475,227 over the last quarter. 0.70% of the stock is currently owned by insiders.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.